Ainos stock analysis
Want to see AIMD full AI Analyst Report?
Ainos (AIMD) Stock Price & Analysis
AIMD Stock Chart & Stats
- Day’s Range
- $1.04 - $1.47
- 52-Week Range
- $0.43 - $3.88
- Previous Close
- $1.23
- Volume
- N/A
- Average Volume (3M)
- 3.61M
- Market Cap
- $9.94M
- Enterprise Value
- $24.22M
- Total Cash (Recent Filing)
- $1.42M
- Total Debt (Recent Filing)
- $13.81M
- Price to Earnings (P/E)
- ―
- Beta
- 2.48
- Next Earnings
- Mar 05, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Scaled AI Nose Demand
The follow-on ASE order indicates progression from initial field validation to larger commercial adoption in semiconductor manufacturing. A repeat customer and materially larger contract could improve revenue visibility, strengthen market credibility, and support working capital as deposits and delivery payments are collected.
Partner-funded VELDONA Licensing
The VELDONA transaction creates multiple potential revenue streams while transferring clinical and regulatory funding and execution to BioPhoenix. Ainos retains core platform ownership and sublicense participation, allowing continued economic upside without carrying the full cost of developing these indications internally.
Chemical Intelligence Platform Expansion
Rapid expansion of the chemical dataset supports product refinement and broader applications for Ainos’s Chemical Intelligence strategy. A larger proprietary information base may improve platform capabilities and help the company serve additional industrial use cases as commercialization and recurring services develop.
Bears Say
Persistent Unprofitable Operations
The current revenue base remains far below the cost structure, with substantial losses continuing across reported periods. Unless commercial agreements convert into sustained volume and improved margins, ongoing operating deficits could constrain investment capacity and delay a credible path to breakeven.
Persistent Cash Burn
Negative operating and free cash flow show that Ainos currently consumes cash rather than funding operations internally. Continued burn increases dependence on customer payments, partner economics, or external financing and could limit the resources available for product development and commercialization.
Shrinking Equity Cushion
The sharp reduction in equity has materially weakened the balance-sheet cushion while leverage has increased. Higher debt relative to equity reduces financial flexibility, makes ongoing losses more consequential, and may constrain Ainos’s ability to absorb execution setbacks or fund expansion without additional capital.
Ainos News
Ainos advances AI Nose into deployment in semiconductor manufacturing
Ainos (AIMD) announced that its second-generation AI Nose platform is advancing into commercial deployment in front-end semiconductor manufacturing, building on validation activities initiated earlier this year involving approximately 200 AI
AIMD FAQ
What was Ainos’s price range in the past 12 months?
What is Ainos’s market cap?
When is Ainos’s upcoming earnings report date?
How were Ainos’s earnings last quarter?
Is Ainos overvalued?
Does Ainos pay dividends?
What is Ainos’s EPS estimate?
How many shares outstanding does Ainos have?
What happened to Ainos’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Ainos?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Ainos
Ainos, Inc. operates as a healthcare technology company, specializing in point-of-care diagnostics and the development of safe, novel treatments for various disease indications. Its current portfolio encompasses a COVID-19 antigen rapid test kit, which integrates with a cloud-based test management platform known as the Ainos App, offering both personal and enterprise applications. Other diagnostic developments include a COVID-19 nucleic acid test and point-of-care testing for volatile organic compounds. Furthermore, the company is progressing with Very Low-Dose Oral Interferon Alpha, an oral formulation engineered to leverage the wide therapeutic applications of IFN-a, and is actively developing a Synthetic RNA (sRNA) technology platform in Taiwan. Established in 1984, this San Diego, California-based firm was formerly known as Amarillo Biosciences, Inc. until its rebranding to Ainos, Inc. in May 2021.
- Sector
- Technology
- Industry
- Biotechnology
- CEO
- Chun-Hsien Tsai
- Employees
- 41
- Website
- www.ainos.com
- Address
- 3050 Post Oak Boulevard, Houston, TX, 77056, US
Ainos (AIMD) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 11 | 5 | 6 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 8 | 0 | 4 |











